A study recently has proved that stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack. The cells, called cardiosphere-derived stem cells, regrew damaged heart muscles and reversed scarring one year later, the authors say.
Date: 21 Feb 2012 – 23 Feb 2012
Place: Florence, Italy
Organized by: ECDC,Istituto Superiore di Sanita’ (ISS)
and Agenzia Sanitaria Locale (ASL)
Epidemiological methods applied to vaccine preventable diseases is a 3 day workshop which will focus on building the capacity to organize, manage, and conduct training on epidemiological methods applied to vaccine-preventable diseases (VPD). The goal is to improve the participants’ skills as trainers.
Malaria has been a serious issue since a long period of time and controlling malaria has been a top goal of international public-health authorities. Caused by parasites transmitted by infected mosquitoes, malaria annually sickens more than 200 million people and kills nearly 800,000, mostly children in Africa. Because children are the most vulnerable to the disease, efforts to develop a vaccine have focused on them.
Momentum is building for the early December staging in Mumbai of the third CPhI India and second P-MEC India pharma ingredients, services and technologies event. A combined total of over 600 exhibitors from over 80 countries are expected at the Bombay Exhibition Centre for the 2009 events, being held on 1 – 3 December.
Building on 8 years of success serving the pharmaceutical industry, Worldwide Business Research is proud to launch Logipharma as Asia's only dedicated conference for pharmaceutical supply chain professionals.
Dr Reddy’s Laboratories (DRL), India’s third-largest pharma company, has seen a sharp rise of 25% in its stock price over the past fifteen trading sessions.
Indian Pharmaceutical Congress Association has organized a mega convention on the pharmaceutical industry in the city from 11 to 13 December, 2009.
x (NYSE: LLY) announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.
Nothing ventured, nothing gained is a popular Spanish proverb elucidating that taking risk is a prerequisite for expecting any higher return.
Genentech, Inc. announced today that an international Phase III study demonstrated that oral Xeloda® plus oxaliplatin (XELOX) is superior to a commonly used intravenous chemotherapy, 5-FU/LV (infused 5-fluorouracil plus leucovorin), in increasing the time people with adjuvant colon cancer lived without their cancer returning when given immediately after surgery.
A report identifying a broad range of potential benefits of incremental pharmaceutical innovation for India would be released later this week by the US India Business Council (USIBC).
Roche announced a new donation to the World Health Organization (WHO) of 5.65 million courses of treatment of the antiviral drug Tamiflu (oseltamivir). This donation includes: replenishment of the Regional Stockpile of 2 million treatment courses of Tamiflu to be held by the WHO and used to address regional outbreaks; replenishment of the Rapid Response Stockpile of 3 million treatment courses of Tamiflu to be held by Roche and deployed under the direction of the WHO; and establishment of a new paediatric stockpile of 650,000 treatment courses of Tamiflu small (30mg and 45mg) capsules.
More doctors are using the Internet to find information on pharmaceutical products. The relationship between sales representative and physician has been the cornerstone of pharmaceutical companies' marketing to the healthcare community for years.
Pharma major, Wockhardt, has been in the news for a while. This was after a flurry of events. Its chairman Habil Khorakiwala resigned elevating his son, Murtuza Khorakiwala to the post of Managing Director.
Janet Woodcock, director of the Center for Drug Evaluation and Research for the US Food and Drug Administration, spoke at the Drug, Chemical, and Associated Technologies Association (DCAT) annual dinner earlier this month, emphasizing the need of regulators and industry to meet the challenge of securing an increasingly complex global pharmaceutical supply chain. Her words were very well taken and show the recognition not only by FDA and other regulatory authorities, but also of pharmaceutical manufacturers and their suppliers, that the elongation of the global supply chain brings with it new responsibilities and ways of doing business.
GlaxoSmithKline and Sanofi-Aventis are reported to be in separate talks to buy a majority stake in Indian biotechnology firm that pioneered indigenous recombinant vaccines, Shantha Biotech.
OSI Pharmaceuticals, Inc. and Genentech, Inc., announced that OSI submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for the use of Tarceva (erlotinib) as a first-line maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) who have not progressed following first-line treatment with platinum-based chemotherapy. Additionally, the companies announced that Roche, their international collaborator for Tarceva, filed an application in Europe with the European Medicines Agency (EMEA).
Avanir Pharmaceuticals has completed targeted enrolment of patients into the STAR trial, a confirmatory phase-III trial of Zenvia (dextromethorphan/quinidine [DM/Q]) in patients exhibiting signs and symptoms of pseudobulbar affect (PBA). The randomized, multi-centre, international STAR trial is designed to compare the effects of Zenvia 30/10 mg, Zenvia 20/10 mg and placebo on involuntary crying/laughing episodes rates.
In its endeavour to help pharma players from other parts of the world to explore Japanese drug market, the second largest in the world, United Business Media, a leading organiser of trade shows and professional shows in Europe, US and Asia, would host its flagship event CPhI Japan at Tokyo Big Sight Exhibition Centre, Tokyo from April 21 to 23, 2009.
The Pharmaceutical Leadership Summit 2009 will be held at Mumbai on April 3, 2009. The event is being held in association with Pharmexcil, Indian Drug Manufacturer's Association (IDMA), Indian Pharmaceutical Associations (IPA) and the Organization of Pharmaceutical Producers of India (OPPI).
